ABOUT FOQUEST®

HELPING PATIENTS

FOQUEST® Offers Flexible Dosing and Administration

FOQUEST® is taken once-daily in the morning, with or without food.1

Start at the lowest possible dose :

Tritrate : Slowly, no less than 5 days apart to the lowest
effective dose. Individual response varies widely.

Wide Range of Strengths to Assist with Titration

Dose should be adjusted individually and slowly to the lowest effective dose in intervals of no less than 5 days.

Sprinkle Option

FOQUEST® capsules can be swallowed whole (never crushed or chewed), but for those who have a tough time swallowing pills, FOQUEST® can also be sprinkled on applesauce, ice cream, or yogurt. FOQUEST® should not be sprinkled on liquids. The entire mixture should be consumed immediately or within 10 minutes, without chewing.

Patients should rinse mouth with water afterwards to ensure that the entire contents are swallowed

Open the capsule

Sprinkle entire contents onto a tablespoon of:

  • Applesauce
  • Ice cream
  • Yogurt

Please see the Product Monograph for complete dosing and administration instructions.

The effect of FOQUEST® might last into the evening, take as soon as possible in the morning to avoid any potential effect on sleep1.

FOQUEST® should not be used in patients with symptomatic cardiovascular disease and should generally not be used in patients with known structural cardiac abnormalities.

Patients who are considered to need extended treatment with FOQUEST® should undergo periodic evaluation of their cardiovascular status.

Do not substitute for immediate release methylphenidate tablets or other controlled release methylphenidate products on a milligram for milligram basis because of differing pharmacokinetic profiles.

FOR PATIENTS NEW TO
METHYLPHENIDATE

25 mg Once daily in the morning
(Usual starting dose)

For patients already taking METHYLPHENIDATE

Start FOQUEST® at the next lower strength
based on total methylphenidate daily dose.

If a dose increase is warranted, titrate no less than 5 days apart to the lowest effective dose.

MAXIMUM DAILY
DOSE FOR CHILDREN &
ADOLESCENTS
(6 TO <18 YEARS):
70 mg

MAXIMUM DAILY
DOSE FOR ADULTS
(≥18 YEARS):
100 mg

An Inside Look at the FOQUEST® tablet

Once-daily FOQUEST® is engineered with Multi-Layer Release (MLR®) Bead Technology1*

FOQUEST® IS DESIGNED TO PROVIDE A BIPHASIC RELEASE OF MPH FROM AN
IMMEDIATE RELEASE LAYER OF THE DRUG, AND DELAYED CONTROLLED RELEASE
LAYERS OF THE DRUG.1

Each bead consists of multiple concentric layers of methylphenidate:1

Select Long-Acting Medications : Methylphenidate
Release by Product and Dosage Strength*

Adapted from the FOQUEST®, BIPHENTIN®, and CONCERTA® product monographs.1,5,6

Please consult respective product monographs for complete dosing information.

FOQUEST® (methylphenidate hydrochloride controlled release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ≥6 years of age.

CONCERTA® (methylphenidate hydrochloride) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6-12 years of age), adolescents (13-18 years of age), and adults (>18 years of age).

BIPHENTIN® (methylphenidate hydrochloride controlled release capsules) is indicated for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6-11 years of age), adolescents (12-18 years of age), and adults (>18 years of age).5

BIPHENTIN® is indicated as an integral part of a total treatment program for ADHD that may include other measures (i.e., psychological, educational, and/or social) for patients with this syndrome. Effectiveness for more than 4 weeks has not been systematically evaluated in placebo-controlled trials. Physicians electing to use Biphentin® for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Click here to consult the product monograph for important information about:

  • contraindications in patients with anxiety, tension, agitation, thyrotoxicosis, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, glaucoma, motor tics, or with a family history or diagnosis of Tourette’s syndrome; concomitant use of an MAO inhibitor and within a minimum of 14 days following discontinuation of an MAO inhibitor.
  • the most serious warnings and precautions regarding drug dependence/tolerance, the potential for abuse, and the need for cautious prescribing, particularly in those with a history of drug dependence or alcoholism because such patients may increase dose on their own initiative, the need for careful supervision during drug withdrawal, and possible need for long-term follow-up.
  • other relevant warnings and precautions regarding: non-interchangeability with other controlled release methylphenidate preparations; misuse of CNS stimulants; the theoretical risk of sudden/cardiac death; risk of sudden cardiac death in: patients with pre-existing structural cardiac abnormalities or other serious heart problems, patients who are involved in strenuous exercise or activities, patients who are using other stimulants or medications for ADHD, or patients who have a family history of sudden cardiac death; cardiovascular effects, pre-existing cardiovascular and cerebral vascular conditions, hypertension; long-term suppression of growth, endogenous or exogenous depression, normal fatigue states, pre-existing psychosis, bipolar disorder, emergence of new psychotic or manic symptoms, aggression, suicidal behaviour and ideation, serotonin syndrome, neurologic effects, ophthalmologic effects, priapism, peripheral vasculopathy including Raynaud’s phenomenon, pregnancy and lactation, an element of agitation, driving and heavy machinery, drug interactions, monitoring and laboratory tests during prolonged therapy.
  • conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

* Comparative clinical significance is unknown